Neurodegenerative Disorders
Sanofi Acquires Vigil Neuroscience for $470 Million, Bolstering Alzheimer’s Drug Pipeline
Sanofi; Vigil Neuroscience; acquisition; Alzheimer’s disease; TREM2 agonist; VG-3927; microglia; neurodegenerative disease; Phase 2 trials; biotech deals
FDA Delays Decision on Biohaven’s Troriluzole for Rare Disease, Plans Advisory Committee Review
Biohaven; FDA delay; troriluzole; spinocerebellar ataxia (SCA); rare disease drug; PDUFA extension; advisory committee; neurodegenerative disease
Azafaros Raises €132M in Series B to Fund Phase 3 Trials for Brain-Penetrant Drug
Azafaros; Series B funding; nizubaglustat; brain-penetrant drug; lysosomal storage disorders; rare neuro-metabolic diseases; phase 3 clinical trials; Jeito Capital; Forbion Growth; neurodegenerative diseases
GSKs newest neuro pact is with ABL Bio, a Sanofi-partnered South Korean biotech
Abetalipoproteinemia, SmithKline Beecham, Bio, Grabody-B, Neurodegenerative Disorders, Blood – brain barrier anatomy, IGF1R gene
TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases
targeted protein degradation, neurodegenerative diseases, TRIM21, TRIMTAC degraders, CNS therapeutics, seed funding, biotech startup
GE HealthCare and UCSF Launch ‘Care Innovation Hub’ to Revolutionize Medical Imaging for Cancer and Neurodegenerative Diseases
GE HealthCare, UCSF, Care Innovation Hub, medical imaging, cancer, neurodegenerative diseases, precision oncology, brain health, automated imaging techniques, MRI, radiopharmaceutical therapies.
Eli Lilly and Alchemab Therapeutics Collaborate on Novel ALS Therapies
Eli Lilly, Alchemab Therapeutics, ALS, Therapeutic Antibodies, Neurodegenerative Disease, Drug Development
Denali Therapeutics’ ALS Drug DNL343 Fails to Meet Primary Efficacy Endpoints in Phase 2/3 HEALEY ALS Platform Trial
Denali Therapeutics, DNL343, ALS (Amyotrophic Lateral Sclerosis), HEALEY ALS Platform Trial, eIF2B agonist, Clinical trial failure, Neurodegenerative diseases
GSK Partners with Muna Therapeutics to Unlock Novel Alzheimer’s Treatments
Muna Therapeutics, GSK, Alzheimer’s disease, neurodegenerative diseases, spatial transcriptomics, MiND-MAP platform, drug discovery, therapeutic targets.
GSK Partners with Muna Therapeutics to Advance Alzheimer’s Treatment Research
GSK, Muna Therapeutics, Alzheimer’s disease, neurodegenerative diseases, drug research, genetic code analysis, neuroscience, collaboration.